Cerebrolysin
Also known as: FPE 1070, Porcine brain hydrolysate
Cerebrolysin (also called FPE 1070 or Porcine brain hydrolysate) is a peptide hydrolysate in the Neurotrophic peptide complex class. Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
For research use only.
Key Facts
- CAS
- 12656-49-6
- Molecular Weight (MW)
- Mixture of low-MW peptides
- Half-life
- Mixture; component PK not a single value
- FDA status
- Not Approved
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Intravenous infusion (the route in the large trials)
- Frequency
- Once daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Neuronal survival pathwaysNeurotrophic signaling
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 9
- Listed offers
- 13
- Median price per mg
- $1.17/mg
- Typical $1.14–$1.62/mg
Research summary
Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Cerebrolysin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Cerebrolysin dosage evidence
Cerebrolysin has no approved dosage in the United States. In the large stroke trials it was dosed by volume: 30 mL once daily by intravenous infusion for 10 days in the CASTA trial (n=1,070), and 30 mL once daily for 21 days alongside rehabilitation in the CARS trial. CASTA did not meet its primary endpoint; CARS reported better arm function at day 90.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous infusion (the route in the large trials) |
| Frequency | Once daily |
| Duration studied | 10–21 days in the stroke trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| CASTA — acute ischaemic stroke in Asia (2012)Clinical trial · Double-blind randomised placebo-controlled trial | Adults with acute ischaemic hemispheric stroke, treated within 12 hours of onset (n=1,070) | 30 mL a day, with aspirin 100 mg a day | Intravenous infusion | Once daily | 10 days | No significant difference on the combined primary endpoint (modified Rankin Scale, Barthel Index, NIHSS) | Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012. |
| CARS — recovery after stroke (2016)Clinical trial · Double-blind randomised placebo-controlled multicentre trial | Adults in early rehabilitation after stroke, treated from 24–72 hours after onset | 30 mL a day | Not stated in the indexed abstract | Once daily | 21 days | Action Research Arm Test score at day 90 favoured cerebrolysin; the authors called the study exploratory | Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. |
Where sources disagree
- Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids prepared from pig brain, not a single peptide, so it is dosed in millilitres rather than milligrams.
- This profile's general route lists intramuscular use, but the large stroke trials gave 30 mL by intravenous infusion. Trial volumes do not transfer to intramuscular injection.
- Results are mixed: the largest trial, CASTA, missed its primary endpoint, while the smaller CARS trial reported a benefit and asked for confirmation in a large trial.
Handling & administration
- Injection Sites
- Abdomen
- Timing Notes
- Administer as a standalone; avoid mixing to preserve balance.
Sequence & molecular data
| Molecular weight | Mixture of low-MW peptides |
|---|---|
| CAS number | 12656-49-6 |
| Half-life | Mixture; component PK not a single value |
| Appearance | Intramuscular injection (solution) |
| Formulation | Solution |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
Origin
Enzymatic hydrolysate of porcine brain proteins.
Targets
Studies
- Cerebrolysin for acute ischaemic stroke
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for vascular dementia
- The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Research statistics
590 PubMed publications · 37.5% human clinical research · 40 registered trials
Counts of published research through 2026-11-08, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Cerebrolysin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Cerebrolysin side effects
The effects below are those reported in Cerebrolysin clinical trials; long-term safety data may still be limited.
Side Effects
- Injection reactions
- Agitation
- Headache
- Rare hypersensitivity
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Cerebrolysin: frequently asked questions
What is Cerebrolysin?
Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.
How does Cerebrolysin work?
Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
Is Cerebrolysin FDA approved?
No. Cerebrolysin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Cerebrolysin?
Reported half-life for Cerebrolysin is Mixture; component PK not a single value. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Cerebrolysin?
Compounds most often compared with Cerebrolysin include Semax, N-Acetyl Semax Amidate, Adamax and Selank. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2023External reference
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials — Neurol Sci, 2017External reference
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2015External reference
- Cerebrolysin for vascular dementia — Cochrane Database Syst Rev, 2013External reference
- The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts — Neuroscience, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Cerebrolysin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cerebrolysin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →